Clinical trial
BIIB014 Phase 2a Monotherapy
NCT00451815 · Biogen, Industry · Withdrawn
Key facts
| NCT number | NCT00451815 |
|---|---|
| Title | BIIB014 Phase 2a Monotherapy |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson's Disease |
| Lead sponsor | Biogen, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | active drug (BIIB014) at 10, 30, 100, or 300 mg once daily., placebo |
| Enrollment | 0 |
| First posted | Mar 26, 2007 |
| Last update posted | Aug 23, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: